Female Urinary Incontinence Management

Treatment Approach

The American College of Physicians recommends non-pharmacological approaches as the first-line treatment for female urinary incontinence, with pharmacological therapy reserved for urgency urinary incontinence after bladder training has been unsuccessful 1, 2, 3
For stress urinary incontinence, pelvic floor muscle training (PFMT) is recommended as the first-line treatment with strong evidence and high-quality evidence 1, 4
Pharmacologic therapy is not recommended for stress urinary incontinence due to strong evidence 4

Bladder training is recommended as the first-line treatment for urgency urinary incontinence with strong recommendation and moderate-quality evidence 2, 4
If bladder training is unsuccessful, pharmacologic therapy is recommended as the second-line treatment 5
The choice of pharmacologic agent should be based on tolerability, adverse effect profile, ease of use, and cost 5
Antimuscarinic agents with lower discontinuation rates (such as solifenacin, darifenacin, and tolterodine) are preferred over those with higher rates (such as oxybutynin) 3, 5

Combined pelvic floor muscle training with bladder training is recommended as the first-line treatment for mixed urinary incontinence with strong recommendation and moderate-quality evidence 3, 6

Solifenacin has the lowest risk for discontinuation due to adverse effects 1
Darifenacin and tolterodine have discontinuation rates similar to placebo 3, 7
Oxybutynin has the highest risk for discontinuation due to adverse effects 3
Antimuscarinic agents commonly cause dry mouth, constipation, and blurred vision 5
β3-adrenoceptor agonists (such as mirabegron) commonly cause nasopharyngitis and gastrointestinal disorders 5

For obese women, weight loss and exercise are recommended with strong evidence and moderate-quality evidence 6
For elderly women, consider lower starting doses of medications due to increased risk of side effects 8
When selecting medication, prioritize tolerability over small efficacy differences 5

Urinary incontinence is underreported and underdiagnosed, and a detailed history is essential 5
Non-pharmacologic approaches are more cost-effective with fewer adverse effects 5
Identify and manage conditions that may cause or worsen urinary incontinence (such as urinary tract infections, metabolic disorders, and excess fluid intake) 8
Review current medications that may contribute to urinary incontinence symptoms 8

Non-pharmacological approaches should be prioritized over pharmacological therapy for SUI, as recommended by the American College of Physicians, with high-quality evidence supporting its effectiveness 9, 10
For postmenopausal women, vaginal estrogen tablets or ovules can be considered as they have demonstrated improvement in UI symptoms, with a number needed to benefit (NNTB) of 5, as suggested by the American College of Obstetricians and Gynecologists 9

Duloxetine has limited efficacy in SUI management, with high-quality evidence showing it did not statistically significantly improve UI compared with placebo, with a NNTB of 13, as reported by the American Urological Association 9, 10
Duloxetine may improve quality of life, but this benefit was not seen in women with severe SUI, with low-quality evidence, as noted by the American College of Physicians 9, 10

For postmenopausal women, vaginal estrogen formulations may be more appropriate as first-line pharmacological therapy, as recommended by the North American Menopause Society 9
Using duloxetine in women with severe SUI or overactive bladder is not recommended, as quality of life improvements have not been demonstrated, as stated by the American Urological Association 9